Latest Listings And Ipos News

Visionflex Group Limited has successfully passed all resolutions at its 2025 Annual General Meeting, reinforcing its governance framework and capital strategy.

Vintage Energy has signed a conditional agreement to acquire Metgasco’s 25% stakes in key Southern Flank gas joint ventures and is considering acquiring Bridgeport’s stakes, aiming to accelerate development of the Vali and Odin gas fields.

Metgasco Ltd has entered a conditional agreement to sell its 25% stake in two gas fields in the Cooper Eromanga Basin to Vintage Energy for $5.9 million, marking a significant shift in its asset portfolio.

Metgasco has agreed to sell its 25% stake in key Cooper Eromanga Basin gas fields to Vintage Energy for $5.9 million, marking a significant shift in its business focus. The deal hinges on Vintage securing funding and acquiring additional interests, with shareholder approval required.

Tartana Minerals partners with Alt Resources in a $2 million joint venture to accelerate exploration of critical metals in Far North Queensland, focusing on tin, tungsten, and rare earth elements.

PhosCo Ltd reports thick, high-grade phosphate intersections at its Gasaat Project in Tunisia, coinciding with phosphate's addition to the US Critical Minerals List. The company plans maiden resource estimates and an updated scoping study to advance project development.

Aspermont Limited’s shares have been suspended from trading due to a critical shortfall in board directors, raising questions about its governance and future compliance.

Novatti Group’s AUDD stablecoin has exceeded $1 billion in transactions on the Stellar blockchain, marking a significant milestone in Australia’s digital payments landscape.

L1 Group Limited has completed its transformative merger between Platinum Asset Management and L1 Capital, creating a $16.7 billion funds under management powerhouse, backed by a $286 million capital raise to fuel growth.

Excelsior Capital has settled its Federal Court dispute with London City Equities, paving the way for a capital return, fully franked dividend, and eventual delisting from the ASX.

Radiopharm Theranostics has secured ethics approval to begin a Phase 1 clinical trial of RAD 402, a pioneering radiotherapeutic targeting advanced prostate cancer using terbium-161. This marks a significant step in developing a potentially safer, more effective treatment option.

K2 Asset Management Holdings Ltd marked a pivotal year with 17% revenue growth and a return to profitability, declaring a fully franked dividend and outlining ambitious growth plans across its core business pillars.